Galegenimab

DB18860InvestigationalProtein Based Therapies

Galegenimab is under investigation in clinical trial NCT03972709 (A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration (AMD)).

Mechanism: Pharmacologically active on Serine protease HTRA1
Curator reviewed
Also known as: Immunoglobulin igg1 fab fragment, anti-(human serine proteinase htra1) (human-mus musculus monoclonal fhtr2163 .gamma.1-chain), disulfide with human-mus musculus monoclonal fhtr2163 .kappa.-chain
Code names: FHTR-2163 · RG-6147 · RO-7171009

Resolves to

Compound

UNIIUTI65JH23LCAS2403683-24-7

Targets

Q92743HTRA1

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Galegenimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account